78 related articles for article (PubMed ID: 27180197)
1. Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis.
Xie X; Zhang L; Chen YZ
Hum Immunol; 2016 Jul; 77(7):609-15. PubMed ID: 27180197
[TBL] [Abstract][Full Text] [Related]
2. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection.
Bhushan A; Ghosh S; Bhattacharjee S; Chinnaswamy S
J Interferon Cytokine Res; 2017 Aug; 37(8):369-382. PubMed ID: 28727946
[TBL] [Abstract][Full Text] [Related]
3. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
[TBL] [Abstract][Full Text] [Related]
4. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.
Fernández-Carrillo C; Coto-Llerena M; González P; Crespo G; Mensa L; Caro-Pérez N; Gambato M; Navasa M; Forns X; Pérez-del-Pulgar S
J Clin Virol; 2014 Oct; 61(2):282-5. PubMed ID: 25130512
[TBL] [Abstract][Full Text] [Related]
5. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C.
Keshvari M; Alavian SM; Behnava B; Pouryasin A; Sharafi H
J Res Med Sci; 2016; 21():72. PubMed ID: 27904617
[TBL] [Abstract][Full Text] [Related]
6. Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Murakawa M; Asahina Y; Kawai-Kitahata F; Nakagawa M; Nitta S; Otani S; Nagata H; Kaneko S; Asano Y; Tsunoda T; Miyoshi M; Itsui Y; Azuma S; Kakinuma S; Tanaka Y; Iijima S; Tsuchiya K; Izumi N; Tohda S; Watanabe M
J Med Virol; 2017 Jul; 89(7):1241-1247. PubMed ID: 28036111
[TBL] [Abstract][Full Text] [Related]
7. Influence of IL10 Gene polymorphisms on the sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy.
Guo P; Li G; Sun X; Wu D
Infect Genet Evol; 2016 Nov; 45():48-55. PubMed ID: 27543394
[TBL] [Abstract][Full Text] [Related]
8. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
9. The evaluation of interferon lambda 4 rs368234815 as a predictor factor in treated patients with chronic hepatitis C genotype 1a infection.
Jalilian S; Latifi SM; Makvandi M; Teimoori A; Azaran A; Parsanahad M; Kayedani G
Indian J Med Microbiol; 2017; 35(2):262-268. PubMed ID: 28681817
[TBL] [Abstract][Full Text] [Related]
10. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
12. Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese.
Lim YP; Peng CY; Liao WL; Hung DZ; Tien N; Chen CY; Chang SY; Chang CY; Tsai FJ; Wan L
J Med Virol; 2013 Jul; 85(7):1206-14. PubMed ID: 23918539
[TBL] [Abstract][Full Text] [Related]
13. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
14. Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil.
de Seixas Santos Nastri AC; de Mello Malta F; Diniz MA; Yoshino A; Abe-Sandes K; Dos Santos SE; de Castro Lyra A; Carrilho FJ; Pinho JR
Arch Virol; 2016 Jun; 161(6):1477-84. PubMed ID: 26973228
[TBL] [Abstract][Full Text] [Related]
15. Interferon-λ4 is a cell-autonomous type III interferon associated with pre-treatment hepatitis C virus burden.
Lu YF; Goldstein DB; Urban TJ; Bradrick SS
Virology; 2015 Feb; 476():334-340. PubMed ID: 25577150
[TBL] [Abstract][Full Text] [Related]
16. Interferon Lambda 4 Polymorphism Predicts Sustained Viral Response in Hepatitis C Virus Patients Irrespective of Hepatitis C Virus Genotypes, Ethnicity or Treatment Regimen: Results From a Meta-Analysis.
Wu Q; Wang C; Chen EQ; Tang H; Li ZZ; Lei XZ
Hepat Mon; 2015 Dec; 15(12):e32707. PubMed ID: 26977165
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients.
Nozawa Y; Umemura T; Katsuyama Y; Shibata S; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Yoshizawa K; Ota M; Tanaka E
Tissue Antigens; 2014 Jan; 83(1):45-8. PubMed ID: 24355007
[TBL] [Abstract][Full Text] [Related]
18. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
19. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
[TBL] [Abstract][Full Text] [Related]
20. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
Holmes JA; Congiu M; Bonanzinga S; Sandhu MK; Kia YH; Bell SJ; Nguyen T; Iser DM; Visvanathan K; Sievert W; Bowden DS; Desmond PV; Thompson AJ
Aliment Pharmacol Ther; 2015 Aug; 42(3):296-306. PubMed ID: 26032235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
